Microbix Biosystems Inc. (MBX.TO)
CAD 0.36
(-5.26%)
CAD 0.36
(-5.26%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -39.48 Thousand CAD | -102.21% |
| 2022 | 1.78 Million CAD | 9.72% |
| 2021 | 1.63 Million CAD | 126.18% |
| 2020 | -6.22 Million CAD | -19611.01% |
| 2019 | 31.91 Thousand CAD | 100.37% |
| 2018 | -8.62 Million CAD | -128.08% |
| 2017 | -3.78 Million CAD | -605.08% |
| 2016 | 748.4 Thousand CAD | 21.89% |
| 2015 | 613.98 Thousand CAD | 263.35% |
| 2014 | 168.97 Thousand CAD | 12162.63% |
| 2013 | 1378.00 CAD | 100.05% |
| 2012 | -2.63 Million CAD | -0.88% |
| 2011 | -2.61 Million CAD | -2.97% |
| 2010 | -2.53 Million CAD | -2.17% |
| 2009 | -2.48 Million CAD | 32.26% |
| 2008 | -3.66 Million CAD | -35.26% |
| 2007 | -2.71 Million CAD | -29.63% |
| 2006 | -2.09 Million CAD | -1766.6% |
| 2005 | 125.52 Thousand CAD | 779.9% |
| 2004 | 14.26 Thousand CAD | 103.92% |
| 2003 | -363.7 Thousand CAD | -623.28% |
| 2002 | 69.5 Thousand CAD | -71.17% |
| 2001 | 241.12 Thousand CAD | 153.56% |
| 2000 | -450.22 Thousand CAD | 90.42% |
| 1999 | -4.7 Million CAD | -123.81% |
| 1998 | -2.1 Million CAD | -2000.0% |
| 1997 | -100 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 2.45 Million CAD | 22.94% |
| 2024 Q2 | 377.73 Thousand CAD | -84.62% |
| 2024 Q3 | 246.74 Thousand CAD | -34.68% |
| 2023 Q3 | -769.1 Thousand CAD | -353.06% |
| 2023 Q2 | -169.75 Thousand CAD | 88.64% |
| 2023 Q1 | -1.49 Million CAD | -159.73% |
| 2023 FY | -39.48 Thousand CAD | -102.21% |
| 2023 Q4 | 1.99 Million CAD | 359.69% |
| 2022 Q2 | 530.36 Thousand CAD | -39.78% |
| 2022 Q1 | 880.77 Thousand CAD | 13.08% |
| 2022 FY | 1.78 Million CAD | 9.72% |
| 2022 Q4 | -575.29 Thousand CAD | -229.49% |
| 2022 Q3 | 444.26 Thousand CAD | -16.23% |
| 2021 Q2 | 807.46 Thousand CAD | 517.24% |
| 2021 FY | 1.63 Million CAD | 126.18% |
| 2021 Q3 | 1.51 Million CAD | 87.77% |
| 2021 Q4 | 778.92 Thousand CAD | -48.63% |
| 2021 Q1 | 130.81 Thousand CAD | 102.63% |
| 2020 Q3 | -440.23 Thousand CAD | -100.99% |
| 2020 Q4 | -4.98 Million CAD | -1031.9% |
| 2020 FY | -6.22 Million CAD | -19611.01% |
| 2020 Q1 | -585.26 Thousand CAD | -1098.92% |
| 2020 Q2 | -219.03 Thousand CAD | 62.58% |
| 2019 Q1 | -119.29 Thousand CAD | 98.54% |
| 2019 Q2 | 391.35 Thousand CAD | 428.05% |
| 2019 FY | 31.91 Thousand CAD | 100.37% |
| 2019 Q4 | -48.81 Thousand CAD | 74.48% |
| 2019 Q3 | -191.32 Thousand CAD | -148.89% |
| 2018 Q3 | 958.00 CAD | 100.28% |
| 2018 Q2 | -342.5 Thousand CAD | -263.87% |
| 2018 Q1 | -94.12 Thousand CAD | 90.68% |
| 2018 Q4 | -8.18 Million CAD | -854577.45% |
| 2018 FY | -8.62 Million CAD | -128.08% |
| 2017 FY | -3.78 Million CAD | -605.08% |
| 2017 Q1 | -3.21 Million CAD | -472.74% |
| 2017 Q4 | -1 Million CAD | -635.35% |
| 2017 Q3 | 188.64 Thousand CAD | -26.78% |
| 2017 Q2 | 257.64 Thousand CAD | 108.01% |
| 2016 Q4 | 862.93 Thousand CAD | 1699.53% |
| 2016 FY | 748.4 Thousand CAD | 21.89% |
| 2016 Q1 | -338.42 Thousand CAD | -183.95% |
| 2016 Q2 | 175.94 Thousand CAD | 151.99% |
| 2016 Q3 | 47.95 Thousand CAD | -72.75% |
| 2015 Q2 | 126.77 Thousand CAD | 6434.69% |
| 2015 Q1 | 1940.00 CAD | 100.55% |
| 2015 Q4 | 403.11 Thousand CAD | 390.68% |
| 2015 Q3 | 82.15 Thousand CAD | -35.2% |
| 2015 FY | 613.98 Thousand CAD | 263.35% |
| 2014 Q3 | 210.56 Thousand CAD | 8.61% |
| 2014 FY | 168.97 Thousand CAD | 12162.63% |
| 2014 Q4 | -351.62 Thousand CAD | -266.99% |
| 2014 Q2 | 193.87 Thousand CAD | 66.9% |
| 2014 Q1 | 116.16 Thousand CAD | -81.73% |
| 2013 Q4 | 635.74 Thousand CAD | 721.59% |
| 2013 Q2 | 169.57 Thousand CAD | 124.17% |
| 2013 Q1 | -701.66 Thousand CAD | -27.8% |
| 2013 Q3 | -102.27 Thousand CAD | -160.32% |
| 2013 FY | 1378.00 CAD | 100.05% |
| 2012 FY | -2.63 Million CAD | -0.88% |
| 2012 Q3 | -906.58 Thousand CAD | -48.76% |
| 2012 Q2 | -609.42 Thousand CAD | -17.71% |
| 2012 Q1 | -517.74 Thousand CAD | -2.49% |
| 2012 Q4 | -549.04 Thousand CAD | 39.44% |
| 2011 Q4 | -505.14 Thousand CAD | 32.21% |
| 2011 Q2 | -629.08 Thousand CAD | 14.34% |
| 2011 Q1 | -734.36 Thousand CAD | -2571.51% |
| 2011 Q3 | -745.15 Thousand CAD | -18.45% |
| 2011 FY | -2.61 Million CAD | -2.97% |
| 2010 Q2 | -576.17 Thousand CAD | 22.14% |
| 2010 Q4 | 29.71 Thousand CAD | 102.37% |
| 2010 FY | -2.53 Million CAD | -2.17% |
| 2010 Q1 | -740.03 Thousand CAD | -3.4% |
| 2010 Q3 | -1.25 Million CAD | -117.29% |
| 2009 Q3 | -672.36 Thousand CAD | -31.11% |
| 2009 Q2 | -512.83 Thousand CAD | 12.14% |
| 2009 Q1 | -583.66 Thousand CAD | -32.62% |
| 2009 FY | -2.48 Million CAD | 32.26% |
| 2009 Q4 | -715.66 Thousand CAD | -6.44% |
| 2008 Q3 | -945.11 Thousand CAD | 28.94% |
| 2008 Q4 | -440.11 Thousand CAD | 53.43% |
| 2008 Q2 | -1.33 Million CAD | -31.33% |
| 2008 Q1 | -1.01 Million CAD | -24.41% |
| 2008 FY | -3.66 Million CAD | -35.26% |
| 2007 Q4 | -814 Thousand CAD | 13.46% |
| 2007 Q3 | -940.62 Thousand CAD | -98.01% |
| 2007 Q2 | -475.05 Thousand CAD | 1.47% |
| 2007 Q1 | -482.12 Thousand CAD | 67.33% |
| 2007 FY | -2.71 Million CAD | -29.63% |
| 2006 Q4 | -1.47 Million CAD | -532.01% |
| 2006 Q3 | -233.47 Thousand CAD | 15.68% |
| 2006 Q2 | -276.9 Thousand CAD | -161.1% |
| 2006 FY | -2.09 Million CAD | -1766.6% |
| 2006 Q1 | -106.05 Thousand CAD | 10.27% |
| 2005 Q2 | 132.23 Thousand CAD | 194.35% |
| 2005 FY | 125.52 Thousand CAD | 779.9% |
| 2005 Q1 | 44.92 Thousand CAD | -90.94% |
| 2005 Q4 | -118.19 Thousand CAD | -277.55% |
| 2005 Q3 | 66.56 Thousand CAD | -49.66% |
| 2004 FY | 14.26 Thousand CAD | 103.92% |
| 2004 Q2 | -55.23 Thousand CAD | 63.27% |
| 2004 Q3 | -276.13 Thousand CAD | -399.92% |
| 2004 Q4 | 496.01 Thousand CAD | 279.63% |
| 2004 Q1 | -150.37 Thousand CAD | -654.3% |
| 2003 Q3 | -101.76 Thousand CAD | -30.56% |
| 2003 Q2 | -77.95 Thousand CAD | 52.49% |
| 2003 Q1 | -164.05 Thousand CAD | -209.43% |
| 2003 FY | -363.7 Thousand CAD | -623.28% |
| 2003 Q4 | -19.93 Thousand CAD | 80.41% |
| 2002 Q2 | 33.32 Thousand CAD | 117.56% |
| 2002 Q4 | 149.91 Thousand CAD | 97.2% |
| 2002 Q3 | 76.02 Thousand CAD | 128.13% |
| 2002 FY | 69.5 Thousand CAD | -71.17% |
| 2002 Q1 | -189.75 Thousand CAD | -756.79% |
| 2001 Q4 | -22.14 Thousand CAD | -131.08% |
| 2001 Q3 | 71.26 Thousand CAD | -32.53% |
| 2001 Q2 | 105.61 Thousand CAD | 22.25% |
| 2001 Q1 | 86.39 Thousand CAD | 157.51% |
| 2001 FY | 241.12 Thousand CAD | 153.56% |
| 2000 FY | -450.22 Thousand CAD | 90.42% |
| 2000 Q4 | -150.22 Thousand CAD | 0.0% |
| 2000 Q3 | - CAD | 100.0% |
| 2000 Q2 | -300 Thousand CAD | 0.0% |
| 2000 Q1 | - CAD | 100.0% |
| 1999 Q2 | -600 Thousand CAD | -50.0% |
| 1999 Q3 | -300 Thousand CAD | 50.0% |
| 1999 Q1 | -400 Thousand CAD | -300.0% |
| 1999 Q4 | -3.4 Million CAD | -1033.33% |
| 1999 FY | -4.7 Million CAD | -123.81% |
| 1998 Q4 | -100 Thousand CAD | 66.67% |
| 1998 Q3 | -300 Thousand CAD | 72.73% |
| 1998 Q2 | -1.1 Million CAD | -83.33% |
| 1998 FY | -2.1 Million CAD | -2000.0% |
| 1998 Q1 | -600 Thousand CAD | -200.0% |
| 1997 Q1 | - CAD | 0.0% |
| 1997 Q4 | -200 Thousand CAD | -300.0% |
| 1997 Q3 | 100 Thousand CAD | 0.0% |
| 1997 Q2 | - CAD | 0.0% |
| 1997 FY | -100 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Appili Therapeutics Inc. | -3.78 Million CAD | 98.956% |
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 99.894% |
| Helix BioPharma Corp. | -9.26 Million CAD | 99.574% |
| Medicenna Therapeutics Corp. | -25.46 Million CAD | 99.845% |
| Satellos Bioscience Inc. | -15.88 Million CAD | 99.752% |
| Oncolytics Biotech Inc. | -27.75 Million CAD | 99.858% |
| Sernova Corp. | -38.99 Million CAD | 99.899% |